Arcutis Biotherapeutics Appoints New CMO, Reports Officer Changes
Ticker: ARQT · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | 8-K |
| Filed Date | Apr 10, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $515,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel, officer-appointment
Related Tickers: ARQT
TL;DR
Arcutis just swapped CMOs and is filing an 8-K. Keep an eye on R&D.
AI Summary
Arcutis Biotherapeutics, Inc. announced on April 10, 2024, the appointment of Scott B. Stein as Chief Medical Officer and the departure of Dr. Patrick Mooney from the same role. The company also reported on compensatory arrangements for its officers. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
Changes in key executive roles, particularly the Chief Medical Officer, can signal shifts in the company's strategic direction and focus on research and development.
Risk Assessment
Risk Level: medium — Executive changes can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Arcutis Biotherapeutics, Inc. (company) — Registrant
- Scott B. Stein (person) — Appointed Chief Medical Officer
- Dr. Patrick Mooney (person) — Departed Chief Medical Officer
- April 10, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer for Arcutis Biotherapeutics?
Scott B. Stein has been appointed as the new Chief Medical Officer.
Who previously held the position of Chief Medical Officer?
Dr. Patrick Mooney previously held the position of Chief Medical Officer.
What is the exact date of this 8-K filing?
The date of the earliest event reported is April 10, 2024.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the Commission File Number for Arcutis Biotherapeutics?
The Commission File Number is 001-39186.
Filing Stats: 1,548 words · 6 min read · ~5 pages · Grade level 10.3 · Accepted 2024-04-10 16:15:52
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ARQT The Nasdaq Global Sele
- $515,000 — r will receive an annual base salary of $515,000 (pro-rated for any partial service) and
Filing Documents
- arqt-20240410.htm (8-K) — 37KB
- exh101davidtopperofferof.htm (EX-10.1) — 18KB
- exh102conformedseverance.htm (EX-10.2) — 35KB
- exh991prfordavidtopper.htm (EX-99.1) — 7KB
- exh101davidtopperofferof001.jpg (GRAPHIC) — 194KB
- exh101davidtopperofferof002.jpg (GRAPHIC) — 260KB
- exh101davidtopperofferof003.jpg (GRAPHIC) — 309KB
- exh101davidtopperofferof004.jpg (GRAPHIC) — 304KB
- exh101davidtopperofferof005.jpg (GRAPHIC) — 41KB
- exh101davidtopperofferof006.jpg (GRAPHIC) — 65KB
- exh102conformedseverance001.jpg (GRAPHIC) — 257KB
- exh102conformedseverance002.jpg (GRAPHIC) — 313KB
- exh102conformedseverance003.jpg (GRAPHIC) — 295KB
- exh102conformedseverance004.jpg (GRAPHIC) — 285KB
- exh102conformedseverance005.jpg (GRAPHIC) — 280KB
- exh102conformedseverance006.jpg (GRAPHIC) — 309KB
- exh102conformedseverance007.jpg (GRAPHIC) — 303KB
- exh102conformedseverance008.jpg (GRAPHIC) — 88KB
- exh102conformedseverance009.jpg (GRAPHIC) — 53KB
- exh991prfordavidtopper001.jpg (GRAPHIC) — 189KB
- exh991prfordavidtopper002.jpg (GRAPHIC) — 200KB
- exh991prfordavidtopper003.jpg (GRAPHIC) — 157KB
- 0001787306-24-000046.txt ( ) — 5627KB
- arqt-20240410.xsd (EX-101.SCH) — 2KB
- arqt-20240410_lab.xml (EX-101.LAB) — 23KB
- arqt-20240410_pre.xml (EX-101.PRE) — 13KB
- arqt-20240410_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 10, 2024, the Company issued a press release announcing the appointment of Mr. Topper. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Securities Exchange Act of 1934, as amended, or the Securities Exchange Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Offer Letter of Employment Agreement, dated as of April 5, 2024, by and between David Topper and the Company. 10.2 Severance & Change in Control Agreement, dated as of April 5, 2024, by and between David Topper and the Company. 99.1 Press Release Arcutis Biotherapeutics, Inc., dated April 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUTIS BIOTHERAPEUTICS, INC. Date: April 10, 2024 By: /s/ Todd Franklin Watanabe Todd Franklin Watanabe President and Chief Executive Officer